What cagrilintide is
Cagrilintide is a long-acting amylin analogue being developed for chronic weight management, both alone and with semaglutide as CagriSema. It has a genuine late-stage clinical program, but an investigational ingredient is not interchangeable with an online “research” vial.
Controlled trials show clinically meaningful weight loss
In a 706-participant phase 2 trial, cagrilintide alone produced greater mean weight reduction than placebo at 26 weeks; gastrointestinal events and injection-site reactions were common.[1] In the 3,417-participant REDEFINE 1 phase 3 trial, cagrilintide 2.4 mg plus semaglutide 2.4 mg produced an estimated 20.4% mean weight reduction at 68 weeks versus 3.0% with placebo.[2] A separate phase 3 trial reported benefit in adults with overweight or obesity and type 2 diabetes.[3]
Combination results cannot be attributed entirely to cagrilintide, and trial products, titration, eligibility criteria, monitoring, and follow-up do not validate independently sold material.
Safety and evidence limits
Gastrointestinal adverse events were frequent in REDEFINE 1, affecting 79.6% of the combination group and 39.9% of the placebo group; nausea, vomiting, diarrhea, constipation, and abdominal pain were generally described as transient and mild to moderate.[2] Long-term cagrilintide-specific safety, pregnancy use, interactions, rare events, and outcomes beyond the trial periods remain less certain than for an established approved medicine.
Current U.S. regulatory status
FDA's March 2026 warning letter treated an online cagrilintide product marketed for human use as an unapproved new drug.[4] An FDA substance-registration entry explicitly states that UNII availability does not imply regulatory review or approval.[5] Teloryx therefore presents cagrilintide as investigational trial context and does not publish a consumer dose, titration schedule, or reconstitution recipe. Current status should be rechecked whenever FDA takes a future application action.